title: Can we use mineralocorticoid receptor blockade in diabetic patients with resistant hypertension? Yes we can! But it may be a double-edged sword.
authors.affiliation: aAssistance Publique - Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Hypertension Unit bUniversité Paris-Descartes cINSERM, Clinical Investigation Centre 9201, Paris, France.
authors.forename: Michel
authors.initials: M
authors.lastname: Azizi
authors.forename: Matthieu
authors.initials: M
authors.lastname: Monge
authors.forename: Aurélien
authors.initials: A
authors.lastname: Lorthioir
authors.forename: Guillaume
authors.initials: G
authors.lastname: Bobrie
authors.forename: Laurence
authors.initials: L
authors.lastname: Amar
mesh_terms: D001794:Blood Pressure / Q000187:drug effects*; D048909:Diabetes Complications / Q000188:drug therapy*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D013148:Spironolactone / Q000008:administration & dosage* / Q000627:therapeutic use*
chemical_list: D013148:Spironolactone